Athira Pharma, Inc. (ATHA)
NASDAQ: ATHA · Real-Time Price · USD
0.642
-0.007 (-1.00%)
At close: Nov 20, 2024, 4:00 PM
0.687
+0.045 (6.96%)
Pre-market: Nov 21, 2024, 4:41 AM EST
Athira Pharma Stock Forecast
ATHA's stock price has decreased by -61.99% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Athira Pharma stock have an average target of 11.25, with a low estimate of 0.50 and a high estimate of 22. The average target predicts an increase of 1,651.52% from the current stock price of 0.64.
Analyst Consensus: Buy
* Price targets were last updated on Sep 19, 2024.
Analyst Ratings
The average analyst rating for Athira Pharma stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy → Hold Downgrades $5 → $0.5 | Buy → Hold | Downgrades | $5 → $0.5 | -22.15% | Sep 19, 2024 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 4, 2024 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 4, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $22 | Strong Buy | Initiates | $22 | +3,325.19% | Aug 19, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $19 | Buy | Reiterates | $19 | +2,858.12% | Jun 20, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.55
from -3.09
EPS Next Year
-1.66
from -2.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -2.18 | -0.69 | -0.86 |
| Avg | -2.55 | -1.66 | -0.86 |
| Low | -2.72 | -3.21 | -0.86 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.